Compare · DXCM vs NXGL
DXCM vs NXGL
Side-by-side comparison of DexCom Inc. (DXCM) and NexGel Inc (NXGL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and NXGL operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 5876.4x NXGL ($5.0M).
- Over the past year, DXCM is down 10.6% and NXGL is down 74.3% - DXCM leads by 63.7 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 10 for NXGL).
- DXCM has more recent analyst coverage (25 ratings vs 1 for NXGL).
- Company
- DexCom Inc.
- NexGel Inc
- Price
- $76.59+5.15%
- $0.59+1.07%
- Market cap
- $29.57B
- $5.0M
- 1M return
- +25.71%
- -0.95%
- 1Y return
- -10.56%
- -74.27%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 26
- 10
- Recent ratings
- 25
- 1
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
NexGel Inc
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest NXGL
- NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th
- Chief Executive Officer Levy Adam R. sold $1,172 worth of shares (2,000 units at $0.59), decreasing direct ownership by 0.58% to 342,692 units (SEC Form 4)
- Chief Executive Officer Levy Adam R. sold $7,834 worth of shares (13,000 units at $0.60), decreasing direct ownership by 4% to 344,692 units (SEC Form 4)
- SEC Form PRE 14A filed by NexGel Inc
- NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration
- SEC Form 4 filed by Director Henry Scott Robert
- SEC Form 4 filed by Director Kieser Brian Joseph
- SEC Form 4 filed by Chief Executive Officer Levy Adam R.
- SEC Form 3 filed by new insider Harris Kevin Mcclain
- SEC Form 3 filed by new insider Kieser Brian Joseph